Top News

Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion

August 01, 2023

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

Sandoz Spin-off Gets Green Light from Novartis Board

July 21, 2023

The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.

Novartis Acquires DTx Pharma in Deal Worth Up to $1 Billion

July 20, 2023

Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.

Merck Files Lawsuit Against US Government

June 08, 2023

The complaint alleges that Medicaid price controls implemented in the Inflation Reduction Act will negatively impact biopharmaceutical innovation.

UK Government Boosts AMR Research with Cash Injection

May 24, 2023

UK government supports AMR research with significant cash injection, provided through the Global AMR Innovation Fund (GAMRIF).

Waters Set for Growth in Bioanalytical Characterization with Wyatt Acquisition

May 18, 2023

Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.

FTC Sues to Block Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics

May 16, 2023

In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.

Baxter Divests BioPharma Solutions Department in $4.25 Billion Deal

May 10, 2023

Private investors from Advent International and Warburg Pincus will operate the assets as an independent CDMO.

Merck to Purchase Prometheus Biosciences for $10.8 Billion

April 18, 2023

Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.

Sartorius to Acquire Polyplus in $2.6 Billion Deal

April 05, 2023

Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.